home / stock / ctxr / ctxr news


CTXR News and Press, Citius Pharmaceuticals Inc.

Stock Information

Company Name: Citius Pharmaceuticals Inc.
Stock Symbol: CTXR
Market: NASDAQ
Website: citiuspharma.com

Menu

CTXR CTXR Quote CTXR Short CTXR News CTXR Articles CTXR Message Board
Get CTXR Alerts

News, Short Squeeze, Breakout and More Instantly...

CTXR - Citius Oncology Announces Positive Topline Results from Investigator?Initiated Phase 1 Study of LYMPHIR(TM) in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers PR Newswire Study data from patients with relapsed or refractory gynecologic cancer...

CTXR - Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program PR Newswire Non-dilutive capital supports continued execution and value creation CRANFORD, N.J. , Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or t...

CTXR - Citius Pharmaceuticals Reports First Revenue Following LYMPHIR(TM) Launch

2026-02-13 15:01:28 ET Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) , a biopharmaceutical company focused on first-in-class critical care products, announced its first reported revenue after the successful launch of LYMPHIR(TM). The company generated $3.9 million in revenue from init...

CTXR - Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J. ...

CTXR - Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J. , Feb....

CTXR - Citius Oncology Expands International Distribution of LYMPHIR(TM) to European Union Through Exclusive Agreement with Uniphar

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PR Newswire Third international distribution agreement further advances global access strategy with major markets in Europe CRANFORD, N.J. , Feb. 11,...

CTXR - US Companies Moving the Markets, Morning edition
Fri, Dec 26, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Northann Corp. (NCL) rose 49.4% to $0.256 on volume of 307,511,018 shares Multi Ways Holdings Limited Class A (MWG) rose 38.1% to $0.3496 on volume of 285,283,961 shares SOBR Safe Inc. (SOBR) rose 82.3% to $2.37 on volume of 143,192,051...

CTXR - US Companies Moving the Markets, Evening edition
Wed, Dec 24, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Vivakor Inc. (VIVK) fell 25.3% to $0.0348 on volume of 443,772,977 shares Northann Corp. (NCL) rose 49.4% to $0.256 on volume of 301,448,296 shares Multi Ways Holdings Limited Class A (MWG) rose 38.1% to $0.3496 on volume of 282,998,059...

CTXR - Citius Pharmaceuticals GAAP EPS of -$3.38

2025-12-23 16:35:04 ET More on Citius Pharmaceuticals Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25 Citius Oncology announces $18 million registered direct offering Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings ...

CTXR - Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25

2025-12-23 16:32:47 ET More on Citius Pharmaceuticals Citius Oncology announces $18 million registered direct offering Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for ...

Next 10